Lineage Cell Therapeutics’ Renevia bags CE Mark Approval for EU market
Category: #health  By Mateen Dalal  Date: 2019-09-21
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Lineage Cell Therapeutics’ Renevia bags CE Mark Approval for EU market

Aesthetic medicine is increasingly being used for the treatment of physical impairments such as skin discoloration, excessive fat, scars, skin laxity, wrinkles, cellulite, and liver spots. Customer are seen demanding for resurfacing and non-invasive skin tightening treatments for the past few years which is expected to rise exponentially in the coming years.

Advancements in this field were made recently when Lineage Cell Therapeutics, Inc., a biotechnology company that focuses on innovating novel cell therapies for untreated medical needs, announced that Renevia®, the biotech’s facial aesthetics drug, achieved a Conformité Européenne (CE) Mark.

As per reports, Renevia has obtained a Class III classification with a planned use in adults as a resorbable matrix for generating autologous adipose tissue preparations to augment and restore facial volume after enduring subcutaneous fat loss for the therapy of facial lipoatrophy.

Apparently, the CE Mark will offer the company the right to distribute and market Renevia all over the European Union (EU) and in all other nations that identify the CE Mark.

Speaking on the announcement, Brian M. Culley, Chief Executive Officer, Lineage, said that gaining CE Mark approval for the drug was a significant corporate achievement that validates the company’s capability to produce positive data from clinical studies and direct a supervisory application from a promising registration and review process.

He added that, following the approval, its Board of Directors have allowed it to select a European representative for business development to negotiate and evaluate the partnership prospects for Renevia.

In light of its efforts on developing its three clinical-stage programs for cell therapy, Lineage is also seeking an external collaborator that has the commercial competences and enough knowledge to promote Renevia in the European market, which would provide the biotech firm enough funds to support its novel cell therapy programs.

Reportedly, the company had made headlines earlier when it finally closed its former acquisition of Asterias Biotherapeutics, Inc. As per reports, the company had completed its acquisition through a merger which led Asterias to become a fully-owned subsidiary of the company with all its operations combined with Lineage.

Source Credit: https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-receives-ce-mark-approval-reneviar

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

By Mateen Dalal

The two companies intend to introduce their custom-made sub-6GHz 5G chipsets by the end of 2021. UNISOC has managed to raise around USD 817.20 million for its new venture. Chinese electronics giants including Xiaomi Corp. and Guangdong Oppo Mob...

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

By Mateen Dalal

Twitter, an American microblogging service company, had touted plans of acquiring Clubhouse, an audio chat iPhone app and live drop-in audio networking platform. The deal was estimated to be valued at around USD 4 billion, as per reliable sources. T...

Beyond Meat sets up factory in China to expedite localized innovation

Beyond Meat sets up factory in China to expedite localized innovation

By Mateen Dalal

American plant-based meat substitute producer Beyond Meat has opened a new production facility in China. Apparently, this recent setup is the company’s first facility outside the U.S., making it the only multinational organization solely focusi...